Utilisation en pratique du rituximab en 2nde ligne et au-delà dans le traitement du pemphigus: série rétrospective
- 16 January 2020
- journal article
- research article
- Published by Elsevier BV in Annales de Dermatologie et de Vénéréologie
- Vol. 147 (3), 173-178
- https://doi.org/10.1016/j.annder.2019.08.020
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single centerJournal of the American Academy of Dermatology, 2017
- First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialThe Lancet, 2017
- Incidence et mortalité du pemphigus en FranceAnnales de Dermatologie et de Vénéréologie, 2016
- Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different RegimensActa Dermato-Venereologica, 2015
- Pemphigus Vulgaris: An Evidence-Based Treatment UpdateDrugs, 2015
- Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patientsBritish Journal of Dermatology, 2013
- Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patientsJournal of the American Academy of Dermatology, 2012
- Adjuvant Rituximab Therapy of PemphigusArchives of Dermatology, 2012
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusThe New England Journal of Medicine, 2007
- Immunopathology and molecular diagnosis of autoimmune bullous diseasesJournal of Cellular and Molecular Medicine, 2007